Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01213329 · ClinicalTrials.gov registry record · Phase 4
Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab
A Phase 4 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
NCT01213329 is a Phase 4 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 52 participants.
The verdict
NCT01213329, a Phase 4 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of this study is to check the T and B cells of the immune system in 50 newly transplanted patients whom have received a kidney (50 recipients and 50 donors totaling 100 anticipated participants). This will be done to see how the Standard of Care (SOC) anti-rejection medication, Alemtuzumab (Campath 1-H®) affects these cells- Campath 1-H® reduces the number of T cells produced by one's body.
Interventions
- DRUG Alemtuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2006-02 |
| Est. Completion | 2009-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01213329
The ClinicalTrials.gov registry entry for NCT01213329 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alemtuzumab is the first listed.
NCT01213329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01213329 about?
NCT01213329 is a clinical study titled "Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab". The purpose of this study is to check the T and B cells of the immune system in 50 newly transplanted patients whom have received a kidney (50 recipients and 50 donors totaling 100 anticipated participants). This will be done to see how the Standard of Care (SOC) anti-rejection medication, Alemtuzum...
What is the current status of trial NCT01213329?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2006-02. Estimated completion is 2009-04.
What interventions are being tested in trial NCT01213329?
The interventions under investigation include: Alemtuzumab (DRUG).
Who is sponsoring clinical trial NCT01213329?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.